Eli Lilly

Drug formulary looks to accelerate clinical trial start up

(Image: iStock/JK1991)

The “NCI Formulary” enables investigators to obtain investigational agents for testing in new preclinical or clinical studies.

According to WHO, cancer is a leading cause of death and morbidity in Europe with more than 1.7 million deaths and three million new cases each year. (Image: iStock/Toa55)

QuintilesIMS leading Big Pharma firms in oncology collaboration

The SpaceX Dragon spacecraft nears the International Space Station during the CRS-8 mission to deliver experiments and supplies to the International Space Station. (Image credit: NASA)

Drug development in space: how microgravity enables pharma

WuXi inks CV development and manufacture deal with Eli Lilly in China

WuXi inks CV development and manufacture deal with Eli Lilly in China

Lilly ends Alzheimer’s study contract with UCSD as California judge steps in

Lilly ends Alzheimer’s study contract with UCSD as California judge steps in

Lilly scientists working at an R&D facility

Expansions of in-house R&D will have no impact on CROs, say Pfizer and Lilly

Gilead sells but CMOs make the bestselling HCV pill Sovaldi

Gilead's reliance on CMOs gives firm 'flexibility' says CFO

Biologics demand a boon for CMOs, but a shift to single-use could see more competition

Bio-CMO sector to grow over 40% on Big Biopharma's burgeoning pipelines

TransCelerate launches two new initiatives to accelerate clinical trials

TransCelerate launches two new initiatives to accelerate clinical trials

Lilly inks $450m oncology drug development collaboration in China

Lilly inks $450m oncology drug development collaboration in China

More Eli Lilly